Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

New Orleans-based investment network Gulf South Angels is investing in non-opioid pain drug startup South Rampart Pharma as ...

This leads to relatively smooth (though not flawless) northbound trajectories and strong returns for most stocks over a ...

In this first of a three-part video interview series, Jeffrey Casberg, M.S., vice president of clinical pharmacy at IPD Analytics, shared his input on Managed Healthcare Executive’s annual Pharmacy ...

In January, Vertex achieved a significant milestone with the FDA approval of Suzetrigine, marketed under the brand name Journavx. The approval was the first new class of non-opioid pain medication ...

The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine), an oral NaV1.8 inhibitor, as a treatment for acute pain, representing ...

DAVENPORT, Iowa (KWQC) - The Food and Drug Administration recently approved Journavx to treat short-term pain. It’s a new class of non-opioid pain medication for treating adults and the first ...